A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5-days-on/9-days-off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck

Authors
Category Primary study
JournalMolecular Cancer Therapeutics
Year 2009
This article has no abstract
Epistemonikos ID: 172a43351fa122488c85f5259b4689891a7ae27c
First added on: Mar 01, 2025